Crist Rachael M, Barenholz Yechezkel, Cern Ahuva, Clark Kate N, Cullis Pieter R, Dean Cheryl, Desai Neil, Ferrari Mauro, Germain Matthieu, Giacomantonio Carmen A, Grabarnik Emma, Grodzinski Piotr, Hod Atara, Kennedy Barry E, Kularatne Ruvanthi N, Kwon Glen S, Loeb Emmanuel, Noftall Erin B, Pagliaro Len, Rasoulianboroujeni Morteza, Roth Alexander, Rowles Darren, Singh Kulbir, Steinmetz Nicole F, Yehtina Zhanna, Zhang Yao, Zilbersheid Daniel, Clogston Jeffrey D, Stern Stephan T, Dobrovolskaia Marina A
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Laboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 May-Jun;17(3):e70020. doi: 10.1002/wnan.70020.
The Nanotechnology Characterization Laboratory (NCL) is a US federally funded resource providing characterization and expertise to the cancer nanomedicine research community. Founded as a formal partnership among the US National Cancer Institute (NCI), the US Food and Drug Administration (FDA), and the US National Institute of Standards and Technology (NIST), the NCL has spent two decades developing a one-of-a-kind service with broad multidisciplinary expertise to meet the needs of a rapidly evolving drug development field. To mark the 20th anniversary of the lab's founding, the NCL hosted a symposium to highlight the achievements of the cancer nanomedicine field, showcase novel, next-generation nanotechnology research, and discuss future priorities to enable continued growth in combating cancer and the complexities associated with treating a disease that continues to take millions of lives annually. The discussion topics from this event are summarized.
纳米技术表征实验室（NCL）是一个由美国联邦政府资助的资源机构，为癌症纳米医学研究界提供表征服务和专业知识。NCL是作为美国国立癌症研究所（NCI）、美国食品药品监督管理局（FDA）和美国国家标准与技术研究院（NIST）之间的正式合作关系而成立的，二十年来，它一直致力于开发一种独一无二的服务，拥有广泛的多学科专业知识，以满足快速发展的药物开发领域的需求。为纪念该实验室成立20周年，NCL举办了一次研讨会，以突出癌症纳米医学领域的成就，展示新颖的下一代纳米技术研究，并讨论未来的优先事项，以促进在抗击癌症以及应对每年仍夺走数百万人生命的疾病治疗复杂性方面的持续发展。本文总结了此次活动的讨论主题。
